1 (626) 351-3700

Portfolio

AIVITA Biomedical’s Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival

Personalized cancer vaccine reduces risk of disease progression or death by 38% IRVINE, Calif., Nov. 17, 2020 /PRNewswire/ — AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell applications, today announced data from its multi-center Phase 2 clinical trial of its personalized cancer vaccine, AV-GBM-1, in patients with newly diagnosed glioblastoma (GBM). The […]

AIVITA Biomedical’s Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival Read More »

AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy

— 94% manufacturing success rate achieved for personalized cancer immunotherapy development — IRVINE, Calif., Nov. 2, 2020 /PRNewswire/ — AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell applications, announced today that treatment has been completed for all 57 patients in the Phase 2 clinical trial of AV-GBM-1 in patients with glioblastoma. The

AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy Read More »

Razer launches Xbox edition of Kishi for Android Controller, perfect for xCloud

Earlier this year, Razer launched a fantastic new controller for almost all Android phones with the Nintendo Switch-esque Razer Kishi. Now Razer is rereleasing the Kishi with a new design optimized for Xbox Game Pass and Project xCloud. The biggest difference between the original Razer Kishi and the new Designed for Xbox edition is that

Razer launches Xbox edition of Kishi for Android Controller, perfect for xCloud Read More »

AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management

IRVINE, Calif., Aug. 3, 2020 /PRNewswire/ — AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, announced today the publication of the paper, “An update on GM-CSF and its potential role in melanoma management,” in the journal Melanoma Management. Robert O. Dillman, M.D., chief medical officer at

AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management Read More »

MariaDB Platform X5 Adds New Distributed SQL

REDWOOD CITY, Calif. and HELSINKI – July 16, 2020 – MariaDB® Corporation today announced the general availability of MariaDB Platform X5, a comprehensive open source database solution delivering the ultimate in versatility across workloads and scalability from a single database or data warehouse to millions of transactions per second. This major release introduces powerful upgrades

MariaDB Platform X5 Adds New Distributed SQL Read More »

MariaDB Gives the Power of Analytics to Millions for Free

MariaDB Community Server 10.5 turns into analytics powerhouse with cloud-native storage REDWOOD CITY, Calif. and HELSINKI – June 24, 2020 – MariaDB® Corporation today announced the general availability of MariaDB Community Server 10.5, a major new release that brings high-performance analytics to the hands of millions using the popular open source database. In a push

MariaDB Gives the Power of Analytics to Millions for Free Read More »

MariaDB SkySQL Adds ‘Power Tier’ for Enterprises That Demand Distinction

REDWOOD CITY, Calif. and HELSINKI – May 13, 2020 – MariaDB® Corporation today announced the immediate availability of MariaDB SkySQL Power, the first database-as-a-service (DBaaS) offering that lets enterprises customize options and configurations to fit their distinct requirements. Built on top of SkySQL’s Foundation, which delivers the complete MariaDB Platform experience in the cloud, Power

MariaDB SkySQL Adds ‘Power Tier’ for Enterprises That Demand Distinction Read More »

AIVITA Biomedical Presents Updates from Ongoing Ovarian Cancer and Glioblastoma Clinical Studies at 2020 AACR Virtual Annual Meeting

IRVINE, Calif.–(BUSINESS WIRE)– AIVITA Biomedical, Inc., a biotechnology company specializing in innovative cell therapy applications, announced today that updates from ongoing clinical trials in ovarian cancer and glioblastoma were presented as part of the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I. The presentation from Daniela Bota, MD, Ph.D., of the University

AIVITA Biomedical Presents Updates from Ongoing Ovarian Cancer and Glioblastoma Clinical Studies at 2020 AACR Virtual Annual Meeting Read More »

AIVITA Biomedical Raises $12.5 Million in Series B-2 Financing Round and Announces New Board of Directors Appointee

Leader of Series B-2 Financing Round Matthew Katz Joins AIVITA’s Board of Directors IRVINE, Calif., Feb. 25, 2020 /PRNewswire/ — AIVITA Biomedical, Inc., a biotechnology company (the “Company”) specializing in innovative stem cell applications, announced today the first closing of its $25 million Series B-2 preferred stock investment round. The first closing of $12.5 million was

AIVITA Biomedical Raises $12.5 Million in Series B-2 Financing Round and Announces New Board of Directors Appointee Read More »

Scroll to Top